At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZTS Zoetis
Pre-Mkt 11-02 04:31:47 EST
79.72
+1.45
+1.85%
盘前79.33
-0.39-0.49%
04:30 EST
High80.61Low79.22Vol4.12M
Open79.84D1 Closing78.27Amplitude1.78%
Mkt Cap32.94BTradable Cap32.84BTotal Shares413.22M
T/O328.77MT/O Rate1.00%Tradable Shares412.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: Zoetis Q3 revenue is expected to decrease by 4.42%, and institutional views are cautious
Earnings Agent  ·  10-29
Earning Preview: Zoetis Q3 revenue is expected to decrease by 4.42%, and institutional views are cautious
Zoetis Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains
Dow Jones  ·  10-30
Zoetis Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains
Zoetis Presents Pipeline with Major Market Approvals Expected Annually for Next Several Years
Reuters  ·  10-28
Zoetis Presents Pipeline with Major Market Approvals Expected Annually for Next Several Years
Zoetis Price Target Raised to $85.00/Share from $80.00 by UBS
Dow Jones  ·  10-28
Zoetis Price Target Raised to $85.00/Share from $80.00 by UBS
Zoetis Inc. Stock Underperforms Tuesday When Compared to Competitors
Dow Jones  ·  10-28
Zoetis Inc. Stock Underperforms Tuesday When Compared to Competitors
UBS Adjusts Price Target on Zoetis to $85 From $80, Maintains Neutral Rating
MT Newswires Live  ·  10-27
UBS Adjusts Price Target on Zoetis to $85 From $80, Maintains Neutral Rating
Zoetis Inc : UBS Raises Target Price to $85 from $80
THOMSON REUTERS  ·  10-27
Zoetis Inc : UBS Raises Target Price to $85 from $80
Zoetis (ZTS) Could Be 13% Below Fair Value After FDA Approval
Simply Wall St.  ·  10-26
Zoetis (ZTS) Could Be 13% Below Fair Value After FDA Approval
Zoetis Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-23
Zoetis Inc. Stock Outperforms Competitors on Strong Trading Day
Zoetis Wins FDA Approval for Convenia RTU for Dogs
Reuters  ·  10-21
Zoetis Wins FDA Approval for Convenia RTU for Dogs
Zoetis - Convenia Rtu for Dogs Expected to be Available to Veterinarians in Q1 2027
THOMSON REUTERS  ·  10-21
Zoetis - Convenia Rtu for Dogs Expected to be Available to Veterinarians in Q1 2027
Zoetis Receives FDA Approval for Convenia® Rtu for Dogs (Cefovecin Injectable Suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
THOMSON REUTERS  ·  10-21
Zoetis Receives FDA Approval for Convenia® Rtu for Dogs (Cefovecin Injectable Suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
FDA: Approves Ready-to-Use Cefovecin Injectable for Treatment of Certain Skin Infections in Dogs
THOMSON REUTERS  ·  10-20
FDA: Approves Ready-to-Use Cefovecin Injectable for Treatment of Certain Skin Infections in Dogs
Zoetis Price Target Cut to $83.00/Share from $103.00 by Jefferies
Dow Jones  ·  10-20
Zoetis Price Target Cut to $83.00/Share from $103.00 by Jefferies
Jefferies Downgrades Zoetis to Hold From Buy, Price Target is $83
MT Newswires Live  ·  10-20
Jefferies Downgrades Zoetis to Hold From Buy, Price Target is $83
Will Lower Earnings Outlook Change Zoetis Stock Narrative
Simply Wall St.  ·  10-18
Will Lower Earnings Outlook Change Zoetis Stock Narrative
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Phibro Animal Health (PAHC) and Zoetis (ZTS)
TIPRANKS  ·  10-16
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Phibro Animal Health (PAHC) and Zoetis (ZTS)
Zoetis initiated with a Neutral at Goldman Sachs
TIPRANKS  ·  10-16
Zoetis initiated with a Neutral at Goldman Sachs
Zoetis Inc. Stock Outperforms Competitors on Strong Trading Day
Dow Jones  ·  10-16
Zoetis Inc. Stock Outperforms Competitors on Strong Trading Day
Movement Alert｜Zoetis Intraday Rise 5.11% in Regular Trading, Quarterly Dividend Kept Unchanged
Market Focus  ·  10-16
Movement Alert｜Zoetis Intraday Rise 5.11% in Regular Trading, Quarterly Dividend Kept Unchanged
No data available

Introduction

Company Name.
Zoetis
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Issue price:
--